A stipulation and proposed consent judgment was filed on February 24, 2026, with the Court of Chancery of the State of Delaware. The judgment addresses a stockholder class action complaint filed on February 4, 2026, by the Vladimir Gusinsky Revocable Trust against Context Therapeutics Inc. and its directors. The parties are asking the Court to determine that Article V, Section 2 (three-year director terms) and Article VI, Section 1 (directors removable only for cause) of the Company's Amended and Restated Certificate of Incorporation are invalid and unenforceable. If the Stipulated Judgment is approved by the Court, the action will be dismissed with prejudice, and the Company will file a Certificate of Correction with the Delaware Secretary of State. The 2026 annual meeting of stockholders will be held on June 24, 2026, with a record date of April 27, 2026. The Company intends to propose the election of director nominees to one-year terms at the annual meeting. Stockholders wishing to bring proposals or nominate directors must notify the Corporate Secretary by March 14, 2026, and comply with universal proxy rules by April 13, 2026.